Product development resource
How Much Active Ingredient Can an Oral Strip Hold?
There is no universal milligram limit for an oral strip. Feasible payload depends on active properties, raw-material bulk, film solids, strip area and thickness, mechanical behavior, taste, disintegration and process capability.
Short answer
There is no responsible universal milligram limit for an oral strip. A useful payload answer must connect the target dose to the active’s physical form, the dry mass of the strip, the fraction needed for polymer and other functional ingredients, the acceptable strip area and thickness, and the experience in the mouth. Published literature shows that both low-load and specialized high-active-fraction films can be developed, but those examples do not establish a transferable commercial capacity.
A practical payload screen
Start with four linked questions rather than a single capacity number.
| Question | What to calculate or obtain | What it tells you |
|---|---|---|
| What dose must one serving deliver? | Target active mass and active grade | The non-negotiable product job |
| How many strips may form one serving? | One strip, split serving or flexible direction | The required active mass per unit |
| What dry mass can the proposed geometry carry? | Prototype mass per area × strip area | The approximate total dry unit mass |
| How much of that mass can be active? | Active fraction after matrix, masking and other needs | Whether the concept leaves enough formulation space |
This calculation is a feasibility screen, not proof. It does not show that the wet mix remains uniform, the web dries correctly, the unit tastes acceptable or the process transfers to scale.
What makes the same milligram dose easy or difficult
Two actives at the same labeled dose can behave very differently. A dense, soluble, mild-tasting material may impose less pressure than a low-density, poorly dispersible or intensely bitter powder. Particle size and shape can affect settling, roughness and dose distribution. A concentrated extract may carry less mass but introduce taste, stability or regulatory questions that a larger amount of another grade does not.
| Active characteristic | Possible payload consequence | Evidence needed |
|---|---|---|
| Low bulk density | More volume for the same mass | Raw-material specification and prototype mass/area |
| Poor solubility or dispersibility | Settling, visible particles or non-uniform distribution | Mix hold-time and web-uniformity study |
| Strong bitterness | More masking material or changed release strategy | Sensory prototypes and active-release assessment |
| Moisture sensitivity | Narrower processing and packaging options | Process exposure and packaged stability |
| Large dose | Larger, thicker or multiple strips may be needed | Geometry and serving-architecture prototypes |
These are practical development relationships supported by published formulation principles. The outcome remains product-specific.
Published examples are not design limits
A 2015 review reports the specific commercial Gas-X Thin Strips example as containing more than 50% drug substance per total film weight; a 2023 review repeats that statement. This is a product-specific simethicone example, not a general ODF loading range or evidence that an arbitrary active can occupy the same fraction while meeting taste, mechanics, disintegration, uniformity and stability requirements.
Use published examples to generate hypotheses: Which active form was used? Was it dissolved or dispersed? What were the strip dimensions and total mass? Which polymer and process were used? What performance was actually measured? Unless those conditions resemble the proposed product, the number should not be used as a supplier promise.
Levers available when payload is under pressure
| Lever | What it may improve | Trade-off to examine |
|---|---|---|
| Increase strip area | More dry mass per unit | Larger in-mouth footprint and pack |
| Increase thickness | More capacity | Drying, flexibility, mouthfeel and disintegration |
| Increase active fraction | More dose at the same geometry | Less room for polymer and masking |
| Change active grade | Better density, solubility or dispersion | New sourcing, assay, stability or market review |
| Use more than one strip | Lower load per unit | More units per serving and higher packaging count |
| Change format | Removes film-specific constraint | Different user experience and manufacturing path |
The best lever preserves the product’s intended job. Do not protect “one strip” at the expense of an oversized, unpleasant or unreliable product.
Failure modes that expose a weak payload assumption
Payload pressure may appear as settling in the wet mix, visible particles, mass or content variation across the web, brittle or weak film, tack, poor release from the liner, slow or inconsistent disintegration, rough mouthfeel, persistent residue, unacceptable bitterness, or instability in the proposed pack.
A clear-looking film is not sufficient evidence. Dissolved actives can still create taste, stability or matrix problems; dispersed actives can look acceptable in one sample while distribution changes through the batch or casting run.
What a payload prototype should report
Request a prototype report that connects formulation and process to the finished unit. Depending on classification and development stage, useful evidence may include:
- active identity, grade and target per unit;
- strip dimensions, unit mass and thickness;
- active fraction and total dry solids;
- whether the active is dissolved or dispersed;
- mix hold time and sampling locations;
- mass, thickness, assay and content-uniformity results where applicable;
- mechanical handling, visible defects and release from liner;
- disintegration plus dissolution or release where relevant;
- sensory observations and packaged stability plan.
Test methods and acceptance criteria must be justified for the actual product; this list is not a universal release specification.
Decision framework
Keep the dose decision separate from the format preference.
- Proceed with one strip when a representative prototype supports the dose, geometry, mechanics and oral experience.
- Test a split serving when dose per unit is the main constraint but the film experience still matters.
- Change the active grade or system when bulk, dispersion or taste—not the concept itself—is driving difficulty.
- Compare another format when the required film becomes too large, complex, fragile or expensive for the intended product.
Use oral strips vs capsules for the format decision, and review taste masking alongside payload for bitter actives.
CoManufacturing practical development experience
The following are CoManufacturing development observations for conventional single-layer oral dissolving films. They are not universal ODF specifications, commercial guarantees or maximum capacities. Active properties, raw-material grade, film system, strip dimensions, sensory requirements, target disintegration and process capability can materially change the result.
| Total active loading per strip | Practical interpretation from CoManufacturing development work | Qualification |
|---|---|---|
| Approximately 100–150 mg | Generally a more practical development region for conventional single-layer ODF work | Still requires formulation, sensory, uniformity, process and stability validation |
| Approximately 150–175 mg | Can be explored, with formulation constraints and trade-offs becoming increasingly important | Film thickness, matrix space, taste, mechanics and disintegration need close review |
| Approximately 280 mg | Achieved in an R&D example | Required a substantially thicker film and disintegration exceeded approximately one minute; this is experimental, not a standard commercial specification or universal maximum |
A working strip footprint commonly explored in CoManufacturing development work is around 20 × 30 mm. Final dimensions are determined during trials. Equal milligram loads can behave very differently: a dense, soluble, mild-tasting active may be workable where the same mass of a bulky, poorly dispersible or intensely bitter active is not. Use these observations to frame prototypes, not to approve feasibility without testing.
Common questions
Can a supplier answer payload from the active name alone?
Usually not responsibly. Grade, dose, geometry, sensory target, matrix and process assumptions are needed.
Does a higher active percentage always produce a smaller strip?
Not necessarily. The system still has to form, dry, remain uniform, handle correctly and perform in the mouth.
Is disintegration proof that the dose is released?
No. Disintegration, dissolution and active release answer different questions.
When should a founder change format?
When preserving the film would materially compromise dose, experience, reliability, cost or launch path—and the film experience is not central enough to justify that compromise.
Evidence and sources
Evidence guide: Published evidence — supported by the linked literature. · CoManufacturing experience — practical development observations, not universal specifications. · Supplier-specific — confirm with the supplier being evaluated. · Product-specific validation — prove with the actual formula, process, pack and market.
- Borges et al., “Oral films: Current status and future perspectives: I—Galenical development and quality attributes,” Journal of Controlled Release 206 (2015): 1–19. doi:10.1016/j.jconrel.2015.03.006 · PubMed
- Ferlak, Guzenda and Osmałek, “Orodispersible Films—Current State of the Art, Limitations, Advances and Future Perspectives,” Pharmaceutics 15 (2023): 361. doi:10.3390/pharmaceutics15020361 · Full text
- Oliveira et al., “Oral disintegration films: applications and production methods,” Journal of Food Science and Technology 60 (2023): 2539–2548. doi:10.1007/s13197-022-05589-9 · Full text
- Salawi, “An Insight into Preparatory Methods and Characterization of Orodispersible Film—A Review,” Pharmaceuticals 15 (2022): 844. doi:10.3390/ph15070844 · Full text
- Özakar and Özakar, “Current Overview of Oral Thin Films,” Turkish Journal of Pharmaceutical Sciences 18 (2021): 111–121. doi:10.4274/tjps.galenos.2020.76390 · Full text